Key Highlights

  • Total revenues, net, were USD 99.3 million, compared with USD 71.6 million.
  • Gross profit was USD 66.2 million, compared with USD 42.1 million.
  • VEVYE sales were USD 39.7 million; IHEEZO sales were USD 25.3 million.
  • The TYRVAYA Acquisition closed on October 1 for USD 30.0 million in cash.

Harrow, Inc. (NASDAQ:HROW) reported third quarter 2026 total revenues, net, of USD 99.3 million, compared with USD 71.6 million in the third quarter of 2025, an increase of USD 27.7 million. Reported EPS was USD 0.25 and Revenue was USD 99.30 million, compared with estimates of EPS of USD 0.19 and revenue of USD 98.60 million.

Gross profit was USD 66.2 million, compared with USD 42.1 million. Net Income was USD 9.8 million, compared with USD 1.0 million. For the nine months, total revenues, net, were USD 214.2 million, compared with USD 183.2 million, Gross Profit was USD 128.6 million, compared with USD 95.2 million, and the net loss was USD 35.1 million, compared with USD 11.8 million.

Product Revenue

VEVYE revenue was USD 39.7 million, compared with USD 22.6 million, and USD 90.0 million for the nine months, compared with USD 62.8 million. IHEEZO revenue was USD 25.3 million, compared with USD 21.9 million, and USD 42.8 million for the nine months, compared with USD 45.5 million. The filing notes that VEVYE, IHEEZO and, for the third quarter, TRIESENCE were the products that accounted for more than 10% of revenue in the periods presented.

TYRVAYA Acquisition

On October 1, 2026, the company paid USD 30.0 million in cash at the closing of the TYRVAYA acquisition, funded with cash on hand and without borrowings under its Credit facility. It may be obligated to pay up to an additional USD 70.0 million in contingent milestone payments if specified TYRVAYA net sales thresholds are achieved over twelve month measurement periods ending on or before December 31, 2029.

The company said it anticipates TYRVAYA contributing in excess of USD 30.0 million of revenue in 2027, with approximately USD 20.0 million of new annual operating expenses mainly from expanding its commercial organization, Marketing activities and incremental quality, Supply chain and related services.

Expenses and Financing

Research and development expenses increased USD 7.0 million in the quarter and USD 15.0 million for the nine months, primarily due to Clinical Trials and product formulation work associated with Melt Pharmaceuticals. Net interest expense was USD 6.2 million, compared with USD 6.0 million, and USD 18.0 million for the nine months, compared with USD 19.0 million. The increase in the quarter reflects USD 50.0 million of borrowings issued in March 2026.

Cash on hand at September 30, 2026 was USD 75.3 million, compared with USD 72.9 million at December 31, 2025. The company stated it believes cash and cash equivalents, together with cash generated from operations, are sufficient to sustain planned operations, capital expenditures and the TYRVAYA payments for at least the next 12 months.

Net cash used in Operating Activities was USD 27.4 million for the nine months, compared with USD 35.5 million provided in the prior year period. The company attributed the variance to a USD 23.4 million increase in net loss and an unfavorable change in accounts receivable, which increased by USD 39.0 million in the 2026 period.

Product Lines and TYRVAYA Terms

Harrow's quarter was led by VEVYE sales of USD 39.7 million and IHEEZO sales of USD 25.3 million. The TYRVAYA purchase carried USD 30.0 million paid in cash at closing and up to USD 70.0 million in contingent milestones, and the filing explains the nine month Cash Flow variance.